Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome



Status:Completed
Conditions:Ovarian Cancer, Obesity Weight Loss, Women's Studies
Therapuetic Areas:Endocrinology, Oncology, Reproductive
Healthy:No
Age Range:18 - 40
Updated:2/24/2019
Start Date:July 24, 2017
End Date:June 25, 2018

Use our guide to learn which trials are right for you!

A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of
polycystic ovary syndrome (PCOS) in overweight and obese women.


Key Inclusion Criteria:

- PCOS (diagnosed as clinical or biochemical hyperandrogenism, amenorrhea or
oligomenorrhea and exclusion of other causes of hyperandrogenism.

- Overweight/obese female subjects with BMI of 28 - 45 kg/m^2, inclusive, and stable
weight +/- 3 kg over previous 3 months

- Subjects must use non-hormonal methods of contraception during the study.

Key Exclusion Criteria:

- Subjects with exogenous causes of hirsutism

- Menstruation in the 30 days prior to screening or treatment

- Pregnant or nursing (lactating) women

- Use of prohibited medications

- Preexisting medical condition which may significantly alter the absorption,
metabolism, or excretion of the study drug, or which may jeopardize the subject in
case of participation in the study
We found this trial at
4
sites
Springfield, Missouri 65804
?
mi
from
Springfield, MO
Click here to add this to my saved trials
Baton Rouge, Louisiana 70808
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Berlin,
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19102
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials